Exact-diagonalization study of the spectral-weight functions and the density of states of the lattice Anderson model.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J Callaway.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A variety of different fermentation processes has been successfully employed to produce consistent protein-based biopharmaceuticals from genetically engineered animal cells. Chinese hamster ovary (CHO) cells were genetically modified to produce recombinant human soluble CD4, tissue plasminogen activator (tPA) or erythropoietin (EPO). Soluble CD4 was collected from extended perfused fermentations of several months' duration, during which some quantitative loss of DNA copy level, mRNA expression level, and fermentation titer were observed. In one extended run, a novel contaminant appeared in intermediates purified from later harvests. However, in all cases, the final soluble CD4 product was consistent in terms of purity and potency. Evaluation of genetic stability for tPA examined both biological traits at the cellular level as well as potency, purity and structure of product derived from cells at various levels of in vitro age; no significant cell age effects were observed. Similarly, evaluation of the EPO product showed that genetically-determined and process-determined traits such as potency, tryptic peptide mapping, and sialylation were consistent from lot to lot. These data exemplified how process design, process validation, and in-process and quality control assays can be used effectively to ensure the consistency of recombinant products derived from cell culture fermentations.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
To determine whether the sympathoexcitatory projection from the rostral ventrolateral medulla (RVL) to the sympathetic intermediolateral nucleus (IML) of the spinal cord might use glutamate as an excitatory transmitter, we performed a dual-label, transport and immunocytochemical ultrastructural study. Axon terminals within the IML were examined to determine whether anterogradely transported Phaseolus vulgaris-leucoagglutinin (PHA-L) following injections into the RVL, was colocalized with glutamate immunoreactivity using an antibody to hemocyanin-conjugated L-glutamate (Hepler et al., J. Histochem. Cytochem., 36 (1988) 13-22). Transported PHA-L was visualized with the peroxidase-antiperoxidase technique while glutamate-like immunoreactivity was localized within the same section of the thoracic spinal cord with immunoautoradiography. By light microscopy, PHA-L immunoreactivity was found within a plexus of fine fibers and varicose processes localized to the IML. Silver grains indicative of glutamate immunoreactivity were concentrated over the IML and also over the superficial layers of the dorsal horn. Electron microscopic analysis revealed PHA-L immunoreactivity in axons and axon terminals within the IML. They ranged in diameter from 0.5 to 2.0 microns, contained numerous small clear and 0-3 large, dense-core vesicles, and formed primarily asymmetric synaptic contacts on small dendrites of IML neurons. Some of the PHA-L immunoreactive terminals making asymmetric (excitatory) synaptic contacts on the small dendrites of IML neurons also contained glutamate-like immunoreactivity. We conclude that at least a portion of the input to the IML from the RVL uses glutamate as its transmitter.(ABSTRACT TRUNCATED AT 250 WORDS)
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.